Select a medication above to begin.
Xolair
omalizumab
Black Box Warnings .
Anaphylaxis
has occurred after 1st dose and even after >1y on tx; s/sx incl. bronchospasm, hypotension, syncope, urticaria, and/or tongue/throat angioedema; initiate tx in healthcare setting by healthcare professional prepared for mgmt of anaphylaxis, incl. life-threatening; observe pts for appropriate period after admin; inform pts of s/sx and to seek immed. medical care should any occur; select pts for self-admin. based on criteria to mitigate anaphylaxis risk, incl. no anaphylaxis hx to food (except IgE-mediated food allergy use) or omalizumab or other agents, at least 3 omalizumab doses given w/ healthcare provider guidance w/o hypersensitivity rxn, and caregiver or pt ability to admin. injection, recognize anaphylaxis s/sx, and treat anaphylaxis appropriately
Adult Dosing .
Dosage forms: INJ (auto-injector): 75 mg per 0.5 mL, 150 mg per mL, 300 mg per 2 mL; INJ (pre-filled syringe): 75 mg per 0.5 mL, 150 mg per mL, 300 mg per 2 mL; INJ (vial): 150 mg per 1.2 mL
moderate-severe allergic asthma, maintenance tx
- [150-375 mg SC q2-4wk]
- Info: for pts w/ positive skin test or in vitro reactivity to perennial aeroallergen; individualize dose and frequency based on body wt and baseline IgE levels, see pkg insert; periodically reassess need for tx
chronic rhinosinusitis w/ nasal polyps, maintenance tx
- [75-600 mg SC q2-4wk]
- Info: individualize dose and frequency based on body wt and baseline IgE levels, see pkg insert; periodically reassess need for tx
IgE-mediated food allergy
- [75-600 mg SC q2-4wk]
- Info: individualize dose and frequency based on body wt and baseline IgE levels, see pkg insert; periodically reassess need for tx
chronic spontaneous urticaria
- [150 mg or 300 mg SC q4wk]
- Info: periodically reassess need for tx
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (auto-injector): 75 mg per 0.5 mL, 150 mg per mL, 300 mg per 2 mL; INJ (pre-filled syringe): 75 mg per 0.5 mL, 150 mg per mL, 300 mg per 2 mL; INJ (vial): 150 mg per 1.2 mL
Special Note
- [formulation clarification]
- Info: auto-injector form for use in pts 12 yo and older
moderate-severe allergic asthma, maintenance tx
- [6-11 yo]
- Dose: 75-375 mg SC q2-4wk; Info: for pts w/ positive skin test or in vitro reactivity to perennial aeroallergen; individualize dose and frequency based on body wt and baseline IgE levels, see pkg insert; periodically reassess need for tx
- [12 yo and older]
- Dose: 150-375 mg SC q2-4wk; Info: for pts w/ positive skin test or in vitro reactivity to perennial aeroallergen; individualize dose and frequency based on body wt and baseline IgE levels, see pkg insert; periodically reassess need for tx
IgE-mediated food allergy
- [1 yo and older]
- Dose: 75-600 mg SC q2-4wk; Info: individualize dose and frequency based on body wt and baseline IgE levels, see pkg insert; periodically reassess need for tx
chronic spontaneous urticaria
- [12 yo and older]
- Dose: 150 mg or 300 mg SC q4wk; Info: periodically reassess need for tx
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]